Abstract: The pathophysiological process of diseases is mostly accompanied by the elevated level of oxidative stress, including those reproductive endocrine diseases such as polycystic ovary syndrome, decrease ovarian reserve and premature ovarian failure. Stem cells have been used in the cell therapy or clinical trials of many diseases including endometrial adhesion, polycystic ovary syndrome and premature ovarian failure, in which mesenchymal stem cells (MSC) have distinct advantages over embryonic stem cells (ESC) and induced pluripotent stem cells (iPS). Numerous cytokines secreted by MSC have a regulatory effect on oxidative stress in tissues and cells. It has been found that interleukin-6 (IL-6) and brain-derived neurotrophic factor (BDNF) decrease the level of oxidative stress by the activated Nrf2 pathway. In this paper, the anti-oxidative stress of the cytokins from mesenchymal stem cells is reviewed, as well as its possible intracellular mechanism, so as to provide a new idea for the further clinical trial of the cell therapy with mesenchymal stem cells.

Key words: Mesenchymal stromal cells, Mesenchymal stem cell transplantation, Primary ovarian insufficiency, Brain-derived neurotrophic factor, Interleukin-6；Oxidative stress